V8 Peptides — Engineered Performance
Research Library
AOD-9604 History and Lab Synthesis from hGH Fragments
AOD-9604History

AOD-9604 History and Lab Synthesis from hGH Fragments

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

Where does AOD-9604 come from, and how is it made? AOD-9604 is a synthetic 16-residue peptide modeled on the C-terminal region of human growth hormone (hGH 176–191), with a tyrosine at the N-terminus and one intramolecular disulfide bond. The idea that a growth hormone fragment could carry the lipolytic activity apart from the rest of the protein led to papers in 2000 and 2001 describing its metabolic activity in rodents. Like most peptides of this length it is made by solid-phase synthesis, closed to form the disulfide, purified by HPLC and freeze-dried. The V8 vial is 5 mg, ≥98% HPLC. For laboratory research use only; not for human consumption.

AOD-9604 looks like a simple object, a 16-amino-acid chain with one loop, but both its origin and its manufacture reward a closer look. The origin shows how an old observation about whole growth hormone became a search for the smallest piece that keeps one activity. The manufacture shows what is actually inside a vial and why purity and identity data matter for a disulfide-containing peptide. This page covers both. It deals with chemistry and published history only and is not guidance for use in any living subject. The material is for laboratory research use only.

From a 191-residue hormone to a 16-residue fragment

Human growth hormone is a 191-amino-acid protein with two disulfide bonds. Its metabolic activity has several components, and a recurring question in the field was whether those activities were spread over the whole molecule or localized in particular regions. Work on fragments, where small pieces of the hormone are synthesized and tested in isolation, was the standard way to answer that. The region at the C-terminus attracted interest as a candidate for lipolytic activity. The product page describes AOD-9604 as modeled on that region, the stretch labeled hGH 176–191, and notes that the sequence begins with a tyrosine and has two cysteines joined by a single disulfide that closes part of the chain into a small loop.

The tyrosine is worth a comment. In the native hormone the numbered segment 177–191 is fifteen residues; the 16-residue AOD-9604 carries an additional N-terminal tyrosine that is not part of that numbering. A tyrosine at the end of a synthetic peptide is a conventional choice because its aromatic ring absorbs at 280 nm, which lets the peptide be detected and quantified by simple UV methods and makes radioiodination possible. That is a generic point of peptide design and the sources cited here do not state the original motivation, so regard it as a plausible chemical rationale and not a documented intention.

The published trail

YearPaperWhat the title and record establish
2000Heffernan and colleagues, Am J Physiol Endocrinol MetabReported effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism
2000Ng and colleagues, Horm ResMetabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
2001Heffernan and colleagues, EndocrinologyCompared the effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism
2001Jiang and colleagues, conference proceedingsDescribed the development of an hGH peptide analogue, AOD9604 (title-level evidence only)

These papers are the primary descriptions of the fragment. They are rodent and cell-level studies from the early 2000s; the page does not summarize their numbers because the details depend on the model, route and design, and a laboratory reading them should go to the source. What the set establishes is the order of events: a lipolytic fragment of the hormone was synthesized, studied in animal models of lipid metabolism, and compared directly against the intact hormone. The comparison with full-length hGH is the idea behind the question that the V8 page poses, namely how the fragment's signaling profile compares with that of the intact protein in the same system. For the relationship with the full hormone and with a related fragment, see AOD-9604 vs hGH fragment 176-191.

How a 16-residue disulfide peptide is made

The following is a general account of how peptides of this type are prepared. V8 does not publish its suppliers' process details, so none of this should be read as a description of any particular batch. It is included because knowing the steps tells you which impurities to expect.

Solid-phase assembly

Merrifield introduced solid-phase peptide synthesis in 1963 with the synthesis of a tetrapeptide (Merrifield, 1963). The first residue is anchored to an insoluble resin through its carboxyl end. Each following amino acid, with its amino group protected, is coupled to the growing chain, the protecting group is removed, and the cycle is repeated. Fields and Noble reviewed the now-dominant strategy that uses the 9-fluorenylmethoxycarbonyl (Fmoc) group for the amino terminus (Fields and Noble, 1990). The side chains of reactive residues such as cysteine, arginine, glutamic acid, serine and tyrosine carry their own protecting groups that survive the chain-building steps.

Cleavage and disulfide formation

At the end of assembly, strong acid releases the peptide from the resin and strips the side-chain protection. The two cysteines are now free thiols, and the peptide is a mixture of linear chains. Forming the intramolecular bond is a separate oxidation step, usually carried out in dilute solution to favor loop closure over intermolecular dimerization. Dilution matters: at high concentration, two linear molecules can form a bridge between them instead.

Purification and freeze-drying

The crude product is purified by reversed-phase HPLC, fractions are analyzed, and those that meet the specification are pooled and lyophilized. The result is a dry solid that contains the peptide plus counterions, usually from the acids used in purification, and residual water. That composition is why HPLC purity (an area percentage) differs from net peptide content (a weight percentage). The principle is covered in understanding HPLC purity, and the freeze-drying step in what is lyophilization.

Impurities that follow from the route

Vergote and colleagues discussed the specifications that regulators and developers apply to synthetic peptides and the impurity classes they must account for (Vergote and colleagues, 2009). Each step above can leave a characteristic by-product, and a disulfide peptide has some that others do not.

StepPossible impurityHow it shows up
CouplingDeletion sequences missing one residueEarlier-eluting peaks with lower mass
DeprotectionPeptides with a protecting group still attachedLater-eluting peaks with higher mass
CleavageOxidized tyrosine or methionine-type side reactionsSmall mass shifts
OxidationIntermolecular dimers; open (reduced) form; scrambled productsDimer at about twice the mass; reduced form 2 Da heavier; shoulders on the main peak
IsolationCounterion and water contentNet peptide content below 100% of vial mass

The dimer and reduced-form entries explain why analytical method development for disulfide-containing peptides is one of the uses listed on the product page. A mass-spectrometry identity check can distinguish the closed monomer from the open form because the two differ by two hydrogen masses. The difference between chromatographic and mass-based identity checks is outlined in HPLC vs mass spectrometry, and the compound-specific discussion is in AOD-9604 purity testing.

What is in the V8 vial

According to the AOD-9604 product page, the vial holds 5 mg of lyophilized powder; the purity is ≥98% by HPLC; the molecular formula is C78H123N23O23S2; the sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (176-191); and storage is 2–8 °C, with −20 °C for long-term holding and protection from heat, moisture and light. The batch certificate, where published, is in the COA library. Concentration after reconstitution follows c = m / V, and the calculator does the unit work. Because the molecule contains an oxidation-sensitive disulfide and a tyrosine, avoid reducing agents in any buffer used with it, protect the solution from light and do not shake it.

Reading the history critically

  • Species and model matter. The early papers are in rodents and cells; findings do not transfer automatically to other systems.
  • Fragment and full-length behavior are different questions. A fragment that reproduces one activity may not reproduce others, which is the point of studying it, but a gap in the paper is not proof of absence.
  • Title-level evidence is not data. The 2001 conference item is cited only for its existence and title.
  • Design rationale is often reconstructed after the fact. Statements about why a residue was added should be marked as inference unless the original authors state it.

For the sequence and structure in more detail, see AOD-9604 peptide explained; the broader reference page is the AOD-9604 research overview. Sourcing questions are covered in where to buy AOD-9604, and the material is available through the research catalog for laboratory research use only.

Related reading

Frequently asked questions

What is AOD-9604?

A synthetic 16-residue peptide modeled on the C-terminal region of human growth hormone (hGH 176–191), beginning with a tyrosine and containing one intramolecular disulfide bond.

Where did AOD-9604 originate?

It came from work on fragments of human growth hormone, based on the idea that a lipolytic activity could be localized in the C-terminal region. Papers from 2000 and 2001 described its study in rodent and cell systems.

Which papers first described AOD-9604?

Heffernan and colleagues (2000, 2001) and Ng and colleagues (2000) are the primary descriptions of the fragment and its lipid-metabolism activity in animal and cell models.

How is AOD-9604 made?

By solid-phase peptide synthesis, cleavage from the resin, oxidation to form the disulfide bond, reversed-phase HPLC purification and lyophilization. The account on this page is general and not a description of a specific supplier's process.

Why is the disulfide bond important for analysis?

Oxidation can yield dimers, an open reduced form or scrambled products. Mass spectrometry distinguishes the closed monomer from the reduced form because they differ by two hydrogen masses.

Does 98% HPLC purity mean 98% peptide by weight?

No. It is an area percentage of the chromatographic signal. Counterions and residual water also occupy vial mass, so net peptide content is lower.

What are the vial details for AOD-9604?

The product page lists 5 mg of lyophilized powder, ≥98% purity by HPLC, formula C78H123N23O23S2, stored at 2–8 °C with −20 °C for long-term.

Should reducing agents be used with AOD-9604?

Avoid them in buffers used with the peptide, because they break the disulfide bond and change the molecule under study.

How do I work out the stock concentration?

Divide the vial mass by the diluent volume (c = m / V). The reconstitution calculator handles unit conversions; record lot, diluent and date.

Is the 2001 conference item a data source?

No. It is cited only as evidence that a development program was described under that title; the primary data sit in the 2000 and 2001 journal papers.

Related reading: AOD-9604 Adipocyte Mechanisms: What In Vitro Data Show, AOD-9604 Metabolic Pathway Assays in the Laboratory.

References

  1. Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. doi:10.1210/endo.142.12.8522
  2. Heffernan M, Jiang WJ, Thorburn AW, Ng FM. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab. 2000;279(3):E501-E507. doi:10.1152/ajpendo.2000.279.3.e501
  3. Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. doi:10.1159/000053183
  4. Jiang WJ, Gianello R, Heffernan M, et al. Development of a human growth hormone peptide analogue AOD9604 into an anti-obesity drug. In: Peptides: The Wave of the Future. Springer; 2001:714-715. doi:10.1007/978-94-010-0464-0_333
  5. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
  6. Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 1990;35(3):161-214. doi:10.1111/j.1399-3011.1990.tb00939.x
  7. Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.